IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) SAV006-05 Site 38

Administered By

Awarded By

Contributors

Start/End

  • August 13, 2021 - November 30, 2024